Document:

Exhibit
10.5

 

Registered
#

 

MATEON
THERAPEUTICS,, INC.

16%
CONVERTIBLE UNSECURED NOTE DUE ________, 2021

 

	$25,000.00	July
    23 2020

 

THIS
NOTE IS ISSUED PURSUANT TO AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT OF 1933 (THE “ACT”)
AND QUALIFICATION PROVISIONS OF APPLICABLE STATE SECURITIES LAWS. NEITHER IT NOR THE SHARES OF COMMON STOCK INTO WHICH IT CAN
BE CONVERTED CAN BE SOLD, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS REGISTERED PURSUANT TO THE ACT AND QUALIFIED UNDER APPLICABLE
STATE LAW OR, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY TO MAKER, AN EXEMPTION THEREFROM IS AVAILABLE.

 

FOR
VALUE RECEIVED, the undersigned, Mateon Therapeutics, Inc., a Delaware corporation with offices at 29397
Agoura Road,, Suite 107, Agoura Hills, CA 91301 (“Maker”), promises to pay to _____________(“Payee”),
with                              an
address at ____________________on 2020, except as otherwise provided herein (the “Maturity Date”), the principal
amount of Twenty Five Thousand ($25,000.00) Dollars in lawful money of the United States of America (the “Principal”)
together with all accrued interest.

 

    	Appendix A-1

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 2

    

 

 

NOTE
HOLDER NAME

 

This
Note is one of a series of notes (collectively the “Notes”), all with the same terms and conditions as those set forth
herein, which may be issued by Maker up to the aggregate principal amount of Two Million, Five Hundred Thousand ($2,500,000.00)
Dollars. Each Note is part of an offering (the “Offering”) of up to One Hundred (100) units (the “Units”)
being conducted by Maker. Each Unit consists of one Note in the principal amount of Twenty Five Thousand ($25,000.00) Dollars,
25,000 shares of the Common Stock of EdgePoint AI, Inc., a Delaware corporation, (“EdgePoint”) Maker’s wholly
owned subsidiary, 50,000 three year Warrants (the “EdgePoint Warrants”) each to purchase one share of EdgePoint’s
Common Stock at $1.00 per share and 50,000 three year Warrants (the “Mateon Warrants”) each to purchase one share
of Mateon’s Common Stock at $0.18 per share, each Warrant subject to certain anti dilution provisions. Maker covenants to
Payee that it will invest the entire proceeds of the Offering after all of the Offering expenses are paid in EdgePoint. The Offering
will terminate on the sooner of the sale of all of the Units or June 30, 2020 unless extended at the option of Maker and the placement
agent in the Offering).

 

This
Note is (i) convertible into Maker’s ordinary shares, no par value per share (“Maker’s Common Stock”)
and EdgePoint’s common stock (“EdgePoint’s Common Stock” collectively, with Maker’s Common Stock
the “Common Stock); and (ii) is unsecured all as set forth below. It bears simple interest (the “Interest”)
at the annual rate of sixteen percent (16%), payable, in arrears, on the Interest Payment Dates (as defined in Section 1 below),
until the Principal and all accrued Interest thereon (collectively the “Obligations”) shall be paid in full, or converted
to Common Stock.

 

1.
Interest. Maker will pay Interest on the thirtieth day of each September, December, March, and June, (the “Interest
Payment Dates”) commencing on July 15, 2020. Interest on this Note will accrue from the most recent date to which Interest
has been paid or, if no Interest has been paid, from the date of delivery of this Note. If an Interest Payment Date falls on a
date that is not a Business Day, the Interest shall be payable on the next succeeding Business Day. Interest will be computed
on the basis of a 360-day year of twelve 30-day months. A “Business Day” is any day other than a Saturday, a Sunday
or a day on which commercial banking institutions in New York, New York are authorized by law to be closed.

 

2.
Method of Payment. Maker will pay Principal and Interest in money of the United States that at the time of payment is legal
tender for the payment of public and private debts. Maker may, however, pay Principal and Interest by its check, subject to collection,
payable in such money. It may mail an Interest check to Payee’s address as it first appears on this Note or such other address
as Payee shall give by notice to Maker. Payee must surrender this Note to Maker to collect Principal payments or to convert to
Common Stock. If less than the then outstanding Principal is paid or converted, this Note shall be surrendered only for notation
by Maker of the Principal payment made or converted and returned to Payee. Anything to the contrary notwithstanding, in the event
that Payee converts this Note as provided in Section 3 below, at Payee’s option, Maker shall pay all then accrued
but unpaid Interest in cash or in Common Stock, at the sole discretion of the Maker at the then existing Conversion Rate, as defined
in Section 3(a) below.

 

    	Appendix A-2

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 3

    

 

NOTE
HOLDER NAME

 

3.
Conversion.

 

(a)
Payee’s right to Convert. Except as provided in Paragraph 3(g)(iii) below, Payee shall have the right, at any time commencing
on the date that Maker shall issue this Note to Payee until the close of business on the day the Obligations are paid in full,
to cause the conversion (a “Conversion”) of all or any portion (if such portion is Five Thousand ($5,000) Dollars
or a whole multiple of Five Thousand ($5,000) Dollars) of the Principal, and Interest as provided in Section 2 above, outstanding
at the time such Conversion is effected (the “Convertible Obligations”) into shares of Common Stock (the “Underlying
Shares”). The price for Conversion, subject to adjustment as provided in Section 4 below, shall be Eighteen ($0.18)
Cents per share for Maker’s Common Stock and One ($1.00) Dollar per share for EdgePoint’s Common Stock (the “Conversion
Rate”), subject to adjustment as provided below. Neither Maker nor EdgePoint will issue a fractional share of Common
Stock upon Conversion but will round any fractional share to the nearest share so that if the fraction is less than 0.5 no share
shall be issued and if the fraction is 0.5 or higher Maker shall issue one full share.

 

(b)
Manner of Conversion. Payee may exercise Payee’s Conversion right by completing, executing and sending to Maker a completed
and executed Note Conversion Form appended hereto as Annex A (the “Conversion Notice”) setting forth the amount of
the Convertible Obligations to be converted and providing the other information required in the Conversion Notice. Maker shall
issue the number of Underlying Shares into which the Convertible Obligations are to be converted in accordance with the Conversion
Rate. If required by applicable federal or state securities laws or regulations, Payee shall represent in writing to Maker prior
to the receipt of the Underlying Shares that such Shares will be acquired by Payee for investment only and not for resale or with
a view to the distribution thereof, and shall agree that any certificates representing the Shares may bear a legend, conspicuously
noting such restriction, as Maker shall deem reasonably necessary or desirable to enable it to comply with any applicable federal
and/or state laws or regulations.

 

    	Appendix A-3

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 4

    

 

 

NOTE
HOLDER NAME

 

(c)
Delivery of Certificates Upon Conversion. Certificates for Underlying Shares to be issued upon Conversion shall be transmitted
by Maker’s transfer agent (the “Transfer Agent”) to Payee (A) by crediting the account of Payee’s
prime broker with the Depository Trust Company through its Deposit Withdrawal Agent Commission (“DWAC”) system if
Maker or EdgePoint, as the case maybe, is then a participant in such system and there is either (1) an effective Registration
Statement, as defined in Section 5 below, permitting the issuance of the Underlying Shares to or resale of the Underlying
Shares by Payee or (2) the Underlying Shares are eligible for resale by Payee without volume or manner-of-sale limitations pursuant
to Rule 144 under the Act, or (B) if Maker or EdgePoint, as the case maybe, is not then a participant in the DWAC system and there
is not an effective Registration Statement as aforesaid, by physical delivery of the certificates, bearing the restrictive legends
required by Section 3(b) above if the Underlying Shares are otherwise not publicly tradable or without such restrictive
legends if the Underlying Shares are otherwise publicly tradable or eligible for resale by Payee without volume or manner-of-sale
limitations pursuant to Rule 144, to the address specified by Payee in the Conversion Notice by the date that is three (3) Business
Days after the later of (i) the delivery to Maker of the Conversion Notice or (ii) surrender of this Note (such date, the “Underlying
Share Delivery Date”).

 

(d)
Rescission Rights. If Maker fails to cause the Transfer Agent to transmit to Payee a certificate or the certificates representing
the Underlying Shares pursuant to Paragraph 3.(c) above by the Underlying Share Delivery Date, then, Payee will have the
right to rescind such Conversion, which will terminate on the earlier of the actual delivery of the Underlying Shares or three
(3) Business Days after the Underlying Share Delivery Date.

 

(e)
Partial Conversion. If only a portion of the Convertible Obligations then outstanding is converted, Maker shall deliver to Payee,
together with the aforesaid certificate(s), a new note, in form and substance identical to this Note, except that the principal
amount thereof shall equal that portion of the Obligations then outstanding which has not been converted.

 

    	Appendix A-4

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 5

    

 

 

NOTE
HOLDER NAME

 

(f)
Taxes on Shares Issued. The issue of stock certificates on Conversions of this Note shall be made without charge to Payee for
any tax in respect of such issue. Maker shall not, however, be required to pay any tax which may be payable in respect of any
transfer involved in the issue and delivery of Common Stock in any name other than that of Payee, and Maker shall not be required
to issue or deliver any certificates representing such Common Stock unless and until the person or persons requesting the issue
thereof shall have paid to Maker the amount of such tax or shall have established to the satisfaction of Maker that such tax has
been paid.

 

(g)
Covenants of Maker Relating to Conversion. Maker covenants and agrees that from and after the date hereof and until the date of
repayment of all of the Obligations, or Conversion of all of the Convertible Obligations:

 

(i)
It shall reserve, free from preemptive rights, out of its and EdgePoint’s, as the case may be, authorized but unissued shares,
or out of shares held in its and EdgePoint’s treasury, sufficient shares to provide for the Conversion of this Note from
time to time as this Note is presented for Conversion;

 

(ii)
All Underlying Shares that may be issued upon Conversion of this Note will upon issue be validly issued, fully paid and non-assessable,
free from all taxes, liens and charges with respect to the issue thereof, and will not be subject to the preemptive rights of
any stockholder of Maker or EdgePoint, as the case may be;

 

(iii)
If any Underlying Shares to be provided for the purpose of Conversion of the Convertible Obligations require registration with
or approval of any governmental authority under any federal or state law before such shares may be validly issued upon Conversion,
Maker will in good faith and as expeditiously as possible endeavor to secure such registration or approval, as the case may be,
and Maker’s obligation to deliver shares of the Common Stock upon Conversion of the Convertible Obligations shall be abated
until such registration or approval is obtained; provided, however, that this Note and the Obligations shall remain
outstanding unless paid in full until Maker delivers the Underlying Shares and any then accrued but unpaid Interest to Payee and
in no event shall this Note be converted until Maker effects such delivery; and

 

(iv)
If, and thereafter so long as Maker’s Common Stock shall be or EdgePoint’s Common Stock shall become listed on any
securities exchange, market or other quotation system, Maker will, if permitted by the rules of such exchange, market or other
quotation system, list and keep listed and for sale so long as such Common Stock shall be so listed on such exchange, market or
other quotation system, upon official notice of issuance, all Underlying Shares issuable upon Conversion of the Convertible Obligations.

 

    	Appendix A-5

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 6

    

 

 

NOTE
HOLDER NAME

 

4.
Adjustment in Conversion Rate.

 

(a)
Adjustment for Change in Capital Stock. Except as provided in Paragraph 4 (l) below, if Maker or EdgePoint, as the case may
be, shall (i) declare a dividend on its outstanding Common Stock in shares of its capital stock, (ii) subdivide its
outstanding Common Stock, (iii) combine its outstanding Common Stock into a smaller number of shares, or (iv) issue any
shares of its capital stock by reclassification of its Common Stock (including any such reclassification in connection with a
consolidation or merger in which Maker or EdgePoint, as the case may be, is the continuing corporation), then in each such
case the Conversion privilege and the Conversion Rate in effect immediately prior to such action shall be adjusted so that if
this Note is thereafter converted, Payee may receive the number and kind of shares which Payee would have owned immediately
following such action if Payee had converted this Note immediately prior to such action. Such adjustment shall be made
successively whenever such an event shall occur. The adjustment shall become effective immediately after the record date in
the case of a dividend or distribution and immediately after the effective date in the case of a subdivision, combination or
reclassification. If after an adjustment Payee upon Conversion of this Note may receive shares of two or more classes of
capital stock of Maker or EdgePoint, as the case may be, Maker’s Board of Directors shall determine, in good faith, the
allocation of the adjusted Conversion Rate between or among, as the case may be, the classes of capital stock. After such
allocation, the conversion privilege and conversion rate of each class of capital stock shall thereafter be subject to
adjustment on terms comparable to those applicable to Common Stock in this Section 4.

 

(b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 4(a) above, if at any time Maker or EdgePoint,
as the case may be, grants, issues or sells any rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the “Purchase Rights”), then Payee will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which Payee could have acquired if Payee had
held the number of shares of Common Stock acquirable upon complete conversion of this Note (without regard to any limitations
on exercise hereof), immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
grant, issue or sale of such Purchase Rights.

 

Action
to Permit Valid Issuance of Common Stock. Before taking any action that would cause an adjustment reducing the Conversion Rate
below the then par value, if any, of the shares of Common Stock issuable upon conversion of the Notes, Maker or EdgePoint, as
the case may be, will take all corporate action which may, in the opinion of its counsel, be necessary in order that Maker or
EdgePoint, as the case may be, may validly and legally issue shares of such Common Stock at such adjusted Conversion Rate.

 

(c)
Minimum Adjustment. No adjustment in the Conversion Rate shall be required if such adjustment is less than 2% of the then existing
Conversion Rate; provided, however, that any adjustments which by reason of this Paragraph 4 (d) are not
required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this
Section 4 shall be made to the nearest cent or to the nearest one- hundredth of a share, as the case may be. Anything to
the contrary notwithstanding, Maker or EdgePoint, as the case may be, shall be entitled to make such reductions in the Conversion
Rate, in addition to those required by this Paragraph 4 (d), as it in its discretion shall determine to be advisable in
order that any stock dividends, subdivision of shares, distribution of rights to purchase stock or securities, or distribution
of securities convertible into or exchangeable for stock hereafter made by Maker or EdgePoint, as the case may be, to its stockholders
shall not be taxable.

 

    	Appendix A-6

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 7

    

 

 

NOTE
HOLDER NAME

 

(d)
Referral of Adjustment. In any case in which this Section 4 shall require that an adjustment in the Conversion Rate be
made effective as of a record date for a specified event (the “Conversion Event”), if this Note shall have been converted
after such record date, Maker or EdgePoint, as the case may be, may elect to defer until the occurrence of the Conversion Event
issuing to Payee the shares, if any, issuable upon the Conversion Event over and above the shares, if any, issuable upon such
Conversion Event on the basis of the Conversion Rate in effect prior to such adjustment; provided, however, that
Maker or EdgePoint, as the case may be, shall deliver to Payee a due bill or other appropriate instrument evidencing Payee’s
right to receive such additional shares upon the occurrence of the event requiring such adjustment.

 

(e)
Number of Shares. Upon each adjustment of the Conversion Rate as a result of the calculations made in Paragraphs 4(a) and
(b) above, this Note shall thereafter evidence the right to purchase, at the adjusted Conversion Rate, that number
of shares (calculated to the nearest one-hundredth) obtained by dividing (i) the product obtained by multiplying the number of
shares issuable upon Conversion of this Note prior to adjustment of the number of shares by the Conversion Rate in effect prior
to adjustment of the Conversion Rate by (ii) the Conversion Rate in effect after such adjustment of the Conversion Rate.

 

(f)
When No Adjustment Required. No adjustment need be made for a transaction referred to in Paragraphs 4(a) and (b)
above if Payee is permitted to participate in the transaction on a basis no less favorable than any other party and at a level
that would preserve Payee’s percentage equity participation in the Common Stock upon Conversion of this Note. No adjustment
need be made for sales of Common Stock pursuant to a plan by Maker or EdgePoint, as the case may be, for reinvestment of dividends
or interest, the granting of options and/or the exercise of options outstanding under any of Maker’s or EdgePoint’s,
as the case may be, currently existing stock option plans, the exercise of any other of Maker’s or EdgePoint’s, as
the case may be, currently outstanding options, or any currently authorized warrants, whether or not outstanding. No adjustment
need be made for a change in the par value of the Common Stock, or from par value to no par value or no par value to par value.
If this Note becomes convertible solely into cash, no adjustment need be made thereafter. Interest will not accrue on the
cash.

 

(g)
Notice of Adjustment. Whenever the Conversion Rate is adjusted, Maker shall promptly mail to Payee a notice of the adjustment
together with a certificate from Maker’s Chief Financial Officer briefly stating (i) the facts requiring the adjustment, ( ii) the adjusted Conversion Rate and the manner of computing it, and (iii) the date on which such adjustment
becomes effective. The certificate shall be evidence that the adjustment is correct , absent manifest
error.

 

(i)
Voluntary Reduction. Maker from time to time may reduce the Conversion Rate by any a mount for any period of time if the
period is at least twenty (20) days and if the reduction is irrevocable during the period. Whenever the Conversion Rate is
reduced, Maker shall mail to Payee a notice of the reduction. Maker shall mail the notice at least fifteen (15) days before
the date the reduced Conversion Rate takes effect. The notice shall state the reduced Conversion Rate and the period it will
be in effect. A reduction of the Conversion Rate does not change or adjust the Conversion Rate otherwise in effect for
purposes of Paragraphs 4 (a) and (b) above. Anything to the contrary notwithstanding, this Paragraph 4(i) shall
be void and of no effect if it violates the rules and/or regulations of any exchange or inter-dealer quotation system on
which the Common Stock is then listed for trading.

 

    	Appendix A-7

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 8

    

 

 

NOTE
HOLDER NAME

 

(h)
Prohibition against Certain Reductions of Conversion Rate. Anything to the contrary notwithstanding, in no event shall the Conversion
Rate be reduced below the par value of the Common Stock.

 

(i)
Notice of Certain Transactions. If (i) Maker or EdgePoint, as the case may be, takes any action that would require an adjustment
in the Conversion Rate pursuant to this Section 4; or (ii) there is a liquidation or dissolution of Maker, or EdgePoint,
as the case may be, Maker shall mail to Payee a notice stating the proposed record date for a distribution or effective date of
a reclassification, consolidation, merger, transfer, lease, liquidation or dissolution. Maker shall mail the notice at least fifteen
(15) days before such date. Failure to mail the notice or any defect in it shall not affect the validity of the transaction.

 

(j)
Reorganization of Maker. If Maker and/or the holders of Common Stock are parties to a merger, consolidation or a transaction
in which (i) Maker transfers or leases substantially all of its assets; (ii) Maker reclassifies or changes its outstanding
Common Stock; or (iii) the Common Stock is exchanged for securities, cash or other assets; the person who is the transferee
or lessee of such assets or is obligated to deliver such securities, cash or other assets shall assume the terms of this
Note. If the issuer of securities deliverable upon Conversion of this Note is an affiliate of the surviving, transferee or
lessee corporation, that issuer shall join in such assumption. The assumption agreement shall provide that the Payee may
convert the Convertible Obligations into the kind and amount of securities, cash or other assets that Payee would have owned
immediately after the consolidation, merger, transfer, lease or exchange if Payee had converted this Note immediately before
the effective date of the transaction. The assumption agreement shall provide for adjustments that shall be as nearly
equivalent as may be practical to the adjustments provided for in this Section 4. The successor company shall mail to
Payee a notice briefly describing the assumption agreement. If this Paragraph applies, Paragraph 4 (a) above does not
apply.

 

    	Appendix A-8

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 9

    

 

 

NOTE
HOLDER NAME

 

(k)
Adjustment Upon Issuance of Shares of Common Stock. If and whenever on or after the date hereof, EdgePoint issues or sells, or
in accordance with this section is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of
shares of Common Stock owned or held by or for the account of the Company, but excluding any Exempt Issuance issued or sold or
deemed to have been issued or sold) for a consideration per share (the “New Issuance Price”) less than a price
equal to the Conversion Rate in effect immediately prior to such issue or sale or deemed issuance or sale (such Conversion Rate
then in effect is referred to as the “Applicable Price”) (the foregoing a “Dilutive Issuance”),
then immediately after such Dilutive Issuance, the Conversion Rate then in effect shall be reduced to the New Issuance Price.
For all purposes of the foregoing (including, without limitation, determining the adjusted Conversion Rate and consideration per
share under this section), the following shall be applicable:

 

i.
Issuance of Common Stock Equivalents. If EdgePoint in any manner issues or sells any securities of EdgePoint or any subsidiary
which would entitle the holder thereof to acquire at any time EdgePoint Common Stock, including, without limitation, any
debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable
for, or otherwise entitles the holder thereof to receive, Edge Point Common Stock (collectively, “EdgePoint Common Stock
Equivalents”) (other than EdgePoint Common Stock Equivalents that qualify as Exempt Issuances) and the lowest price
per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange thereof is less than the Applicable
Price, then such share of EdgePoint Common Stock shall be deemed to be outstanding and to have been issued and sold by the EdgePoint
at the time of the issuance or sale of such EdgePoint Common Stock Equivalents for such price per share. For the purposes of this
section, the “lowest price per share for which one share of EdgePoint Common Stock is issuable upon the conversion, exercise
or exchange thereof” shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration (if any) received
or receivable by EdgePoint with respect to one share of Edge Point Common Stock upon the issuance or sale of the EdgePoint Common
Stock Equivalent and upon conversion, exercise or exchange of such EdgePoint EdgePoint Common Stock Equivalent and (y) the lowest
conversion price set forth in such EdgePoint Common Stock Equivalent for which one share of EdgePoint Common Stock is issuable
upon conversion, exercise or exchange thereof minus (2) the sum of all amounts paid or payable to the holder of such EdgePoint
Common Stock Equivalent (or any other person) upon the issuance or sale of such EdgePoint Common Stock Equivalent plus the value
of any other consideration received or receivable by, or benefit conferred on, the holder of such EdgePoint Common Stock Equivalent
(or any other Person). Except as contemplated below, no further adjustment of the Conversion Rate shall be made upon the actual
issuance of such shares of EdgePoint Common Stock upon conversion, exercise or exchange of such EdgePoint Common Stock Equivalents.

 

    	Appendix A-9

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 10

    

 

 

NOTE
HOLDER NAME

 

ii.
Change in Option Price or Rate of Conversion. If the purchase or exercise price provided for in any options, the additional consideration,
if any, payable upon the issue, conversion, exercise or exchange of any EdgePoint Common Stock Equivalents, or the rate at which
any EdgePoint Common Stock Equivalents are convertible into or exercisable or exchangeable for shares of EdgePoint Common Stock
increases or decreases at any time, the EdgePoint Conversion Rate in effect at the time of such increase or decrease shall be
adjusted to the EdgePoint Conversion Rate which would have been in effect at such time had such options or EdgePoint Common Stock
Equivalents provided for such increased or decreased purchase price, additional consideration or increased or decreased conversion
rate, as the case may be, at the time initially granted, issued or sold. For purposes of this section, if the terms of any EdgePoint
Common Stock Equivalent that was outstanding as of the date of issuance of this Note are increased or decreased in the manner
described in the immediately preceding sentence, then such EdgePoint Common Stock Equivalent and the shares of Common Stock deemed
issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or
decrease. No adjustment pursuant to this section shall be made if such adjustment would result in an increase of the Conversion
Rate then in effect.

 

iii.
“Exempt Issuance” means the issuance of (a) shares of EdgePoint Common Stock and options to officers, employees,
or directors of Maker issued pursuant to plans that have been approved by a majority of the board of directors of Maker, (b) securities
upon the exercise or exchange of or conversion of any securities issued in the Offering and/or other securities exercisable or
exchangeable for or convertible into shares of EdgePoint Common Stock issued and outstanding on the date immediately prior to
the initial closing of this Offering, provided that such securities and any term thereof have not been amended since such date
to increase the number of such securities or to decrease the issue price, exercise price, exchange price or conversion price of
such securities, (c) full or partial consideration in connection with a strategic merger, acquisition, consolidation or purchase
of substantially all of the securities or assets of a corporation or other entity which holders of such securities or debt are
not at any time granted any registration rights but shall not include a transaction in which EdgePoint is issuing securities primarily
for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) securities in connection
with strategic license agreements and other partnering arrangements so long as such issuances are not primarily for the purpose
of raising capital and which holders of such securities or debt are not at any time granted registration rights.

 

5.
Right to Registration. Payee has the right to require Maker to register the resale of the Underlying Shares and the shares
issuable upon exercise of the Warrants owned by Payee (the “Warrant Shares”) under the Act pursuant to a registration
statement (a “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”)
in accordance with the terms of an agreement (the “Registration Rights Agreement”) dated as of the date hereof among
Maker, Payee and the holders of the other Notes. The date that the first Registration Statement filed pursuant to the Registration
Rights Agreement is declared effective by the Commission is herein referred to as the “Effective Date.”

 

    	Appendix A-10

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 11

    

 

 

NOTE
HOLDER NAME

 

6.
Covenants. Maker covenants and agrees that from and after the date hereof and until the date of repayment or conversion
to Common Stock in full of the Obligations it shall comply with the following conditions:

 

(i)
Maintenance of Existence and Conduct of Business. Maker shall cause EdgePoint and each of its other subsidiaries, if any, to (A)
do or cause to be done all things necessary to preserve and keep in full force and effect its corporate existence and rights;
and (B) continue to conduct its business so that the business carried on in connection therewith may be properly and advantageously
conducted at all times.

 

(ii)
Books and Records. Maker shall cause EdgePoint and each of its other subsidiaries, if any, to keep adequate books and records
of account with respect to its business activities.

 

(iii)
Insurance. Maker shall cause EdgePoint and each of its subsidiaries, if any, to maintain insurance policies insuring such risks
as are customarily insured against by companies engaged in businesses and/or with property similar to those operated and/or owned
or leased by Maker, EdgePoint or any such other subsidiaries, as the case may be, including but not limited to, insurance policies
covering real property. All such policies are to be carried with reputable insurance carriers and shall be in such amounts as
are customarily insured against by companies with similar assets and properties engaged in a similar business.

 

(iv)
Compliance with Law. Maker shall cause EdgePoint and each of its other subsidiaries, if any, to comply in all material respects
with all federal, state, local and foreign laws and regulations applicable to it or such subsidiaries, as the case may be, which,
if breached, would have a material adverse effect on Maker’s, EdgePoint’s or such other subsidiaries’, as the
case may be, business, prospects, operations, properties, assets or condition (financial or otherwise).

 

(v)
Compliance with Material Agreements, Leases, Licenses and Financial Obligations. All of the terms of each of Maker’s, EdgePoint’s
and/or its other subsidiaries’, if any, and affiliates’, material agreements, leases, licenses and financial obligations
shall be complied with, and each of them shall be kept in full force and effect in accordance with their respective terms.

 

7.
Reorganization of Maker. If Maker is party to a merger, consolidation or a transaction in which it is not the surviving
or continuing entity or transfers or leases all or substantially all of its assets, the person who is the surviving or continuing
entity or is the transferee or lessee of such assets shall assume the terms of this Note and the Obligations.

 

8.
Representations and Warranties of Maker. Maker represents and warrants that: (i) it, EdgePoint and each of its other subsidiaries,
if any, is a corporation or other entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization and has all requisite power to carry on its business as now conducted and to own its properties and assets
it now owns; (ii) it, EdgePoint and each of its other subsidiaries, if any, is duly qualified or licensed to do business as a
foreign corporation or other entity in good standing in the jurisdictions in which ownership of property or the conduct of its
business requires such qualification except jurisdictions in which the failure to qualify to do business will have no material
adverse effect on its business, prospects, operations, properties, assets or condition (financial or otherwise); (iii) it, EdgePoint
and each of its other subsidiaries, if any, and/or affiliates thereof, holds all licenses and otherwise complies with all laws,
rules and regulations required to permit it to own its property and conduct its business in the jurisdictions in which it owns
its property and conducts its business; (iv) it has full power and authority to execute and deliver this Note, and that the execution
and delivery of this Note will not result in the breach of or default under, with or without the giving of notice and/or the passage
of time, any other agreement, financial instrument, arrangement or indenture to which it is a party or by which it or EdgePoint
may be bound, or the violation of any law, statute, rule, decree, judgment or regulation binding upon it; (v) it, and each of
its subsidiaries, if any, is in material compliance with all of its financial obligations and all of its material agreements;
(vi) there is no action, suit, proceeding, or investigation pending or currently threatened against it, EdgePoint or any of its
other subsidiaries, if any; and (vii) it has taken and will take all acts required, including but not limited to authorizing the
signatory hereof on its behalf to execute this Note, so that upon the execution and delivery of this Note, it shall constitute
the valid and legally binding obligation of Maker enforceable against Maker in accordance with the terms thereof.

 

    	Appendix A-11

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 12

    

 

 

NOTE
HOLDER NAME

9.
Defaults and Remedies.

 

(a)
Events of Default. The occurrence or existence of any one or more of the following events or conditions (regardless of the reasons
therefor) shall constitute an “Event of Default” hereunder:

 

(i)
Maker shall fail to make any payment of Principal or Interest when due and payable or declared due and payable pursuant to the
terms hereof and such failure shall remain uncured for a period of thirty (30) days thereafter;

 

(ii)
Maker shall fail at any time to be in material compliance with any of the covenants set forth in Section 3(c) or Section
7 of this Note, or, except as provided in Section 3(h) above, shall fail at any time to be in material compliance with
or neglect to perform, keep or observe any of the provisions of this Note to be complied with, performed, kept or observed by
Maker and such failure shall remain uncured for a period of thirty (30) days after notice thereof has been given by Payee to Maker;

 

(iii)
Any representation or warranty made in this Note by Maker shall be untrue or incorrect in any material respect as of the date
when made or deemed made;

 

(iv)
Maker shall commit an Event of Default in any of the other Notes as that term is defined therein;

 

(v)
Any money judgment, writ or warrant of attachment, or similar process not covered by insurance in excess of Fifty Thousand ($50,000)
Dollars in the aggregate shall be entered or filed against Maker, EdgePoint or any of its other subsidiaries, if any, or any of
their properties or other assets and shall remain unpaid, unvacated, unbonded or unstayed for a period of thirty (30) days;

 

(vi)
Maker, EdgePoint or any of its other subsidiaries, if any, shall make an assignment for the benefit of creditors or shall be unable
to pay its debts as they become due;

 

(vii)
Maker, EdgePoint or any of its other subsidiaries, if any, shall have received a written notice of default related to any material
agreement to which it is a party and such act of default shall remain uncured after any applicable cure period;

 

    	Appendix A-12

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 13

    

 

 

NOTE
HOLDER NAME

 

(viii)
A case or proceeding shall have been commenced against Maker, EdgePoint or any of its other subsidiaries, if any, (each a “Proceeding
Company”) in a court having competent jurisdiction seeking a decree or order in respect of a Proceeding Company (A) under
Title 11 of the United States Code, as now constituted or hereafter amended, or any other applicable federal, state or foreign
bankruptcy or other similar law; (B) appointing a custodian, receiver, liquidator, assignee, trustee or sequestrator (or similar
official) of a Proceeding Company, or any of its properties; or (C) ordering the winding-up or liquidation of the affairs of a
Proceeding Company, and such case or proceeding shall remain unstayed or un- dismissed for a period of sixty (60) consecutive
days or such court shall enter a decree or order granting the relief sought in such case or proceeding; or

 

(ix)
A Proceeding Company shall (A) file a petition seeking relief under Title 11 of the United States Code, as now constituted or
hereafter amended, or any other applicable federal, state or foreign bankruptcy or other similar law; or (B) consent to the institution
of proceedings there under or to the filing of any such petition or to the appointment of or the taking of possession by a custodian,
receiver, liquidator, assignee, trustee or sequestrator (or similar official) of such Proceeding Company, or any of its properties.

 

(b)
Remedies. Upon the occurrence of an Event of Default specified in Paragraphs 9(a) (viii) and (ix) above, all Obligations
then remaining unpaid hereunder shall immediately become due and payable in full, plus interest on the unpaid portion of the Obligations
at the highest rate permitted by applicable law, without notice to Maker and without presentment, demand, protest or notice of
protest, all of which are hereby waived by Maker together with all reasonable costs and expenses of the collection and enforcement
of this Note, including reasonable attorney’s fees and expenses, all of which shall be added to the amount due under this
Note. Upon the occurrence of any other Event of Default, the holders of no less than 50.1% in principal amount of the Notes may
thereafter, at their option immediately by notice to Maker, declare all Obligations then remaining unpaid or converted to Common
Stock hereunder immediately due and payable, whereupon the same shall forthwith mature and become due and payable, without any
further notice to Maker and without presentment, demand, protest or notice of protest, all of which are hereby waived by Maker.
Upon a declaration of acceleration, the entire Obligations then remaining unpaid or not converted to Common Stock hereunder shall
become immediately due and payable in full plus interest on the unpaid portion of the Obligations at the highest rate permitted
by applicable law and all reasonable costs and expenses of the collection and enforcement of this Note, including reasonable attorney’s
fees and expenses, all of which shall be added to the amount due under this Note. The rights, powers, privileges and remedies
of Payee pursuant to the terms hereof are cumulative and not exclusive of any other rights, powers, privileges and remedies that
Payee may have under this Note or any other instrument or agreement.

 

    	Appendix A-13

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 14

    

 

 

NOTE
HOLDER NAME

 

10.
Maker’s Right to Convert Note. On or after the earlier of the Effective Date as long as a Registration Statement
remains effective or the date on which the Underlying Shares may otherwise be sold publicly without restriction pursuant to Rule
144 of the Act, Maker may, at its option, convert all of this Note, but not any portion thereof, in accordance with the provisions
of Section 3 above at any time on not less than thirty (30) days’ prior written notice, provided that the daily average
weighted trading price of Maker’s Common Stock equals or exceeds either $2.00 per share regarding EdgePoint or $0.50 per
share regarding Mateon for a period of thirty (30) consecutive trading days (which period must commence after the Effective Date)
ending one trading day prior to the notice of redemption. If this Note is converted pursuant to the terms of this Section 10
then all of the Notes must be converted.

 

11.
Acknowledgment of Payee’s Investment Representations. By accepting this Note, Payee acknowledge that this Note has
not been and will not be registered under the Act or qualified under any state securities laws and that the transferability thereof
is restricted by the registration provisions of the Act as well as the qualification provisions of such state laws. Based upon
the representations and agreements being made by Payee herein, this Note is being issued to Payee pursuant to an exemption from
such registration provided by Section 4 (2) of the Act and Rule 506 promulgated there under, and such applicable state securities
law qualification exemptions. Payee represents that Payee is acquiring this Note for Payee’s own account, for investment
purposes only and not with a view to resale or other distribution thereof, or with the intention of selling, transferring or otherwise
disposing of all or any part of it for any particular event or circumstance, except selling, transferring or disposing of it only
upon full compliance with all applicable provisions of the Act, the Securities Exchange Act of 1934, the Rules and Regulations
promulgated by the Commission there under, and any applicable state securities laws. Payee further understands and agree that
no transfer of this Note shall be valid unless made in compliance with the restrictions set forth on the front of this Note, effected
on Maker’s books by the registered holder hereof, in person or by an attorney duly authorized in writing, and similarly
noted hereon. Maker may charge Payee a reasonable fee for any re registration, transfer or exchange of this Note.

 

12.
Limitation of Interest Payments. Nothing contained in this Note or in any other agreement between Maker and Payee requires
Maker to pay or Payee to accept Interest in an amount that would subject Maker to any penalty or forfeiture under applicable law.
In no event shall the total of all charges payable hereunder, whether of Interest or of such other charges that may or might be
characterized as interest, exceed the maximum rate permitted to be charged under the laws of the states of California or New York.
Should Payee receive any payment, which is or would be in excess of that permitted to be charged under such laws, such payment
shall have been and shall be deemed to have been made in error and shall automatically be applied to reduce the Principal outstanding
on this Note.

 

13.
Miscellaneous.

 

(a)
Effect of Forbearance. No forbearance, indulgence, delay or failure to exercise any right or remedy by Payee with respect to this
Note shall operate as a waiver or as an acquiescence in any default.

 

    	Appendix A-14

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 15

    

 

 

NOTE
HOLDER NAME

 

(b)
Effect of Single or Partial Exercise of Right. No single or partial exercise of any right or remedy by Payee shall preclude any
other or further exercise thereof or any exercise of any other right or remedy by Payee.

 

(c)
Governing Law; Venue. This Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed
by, the internal laws of the State of California applicable to contracts made and to be performed entirely within such State.
Any action, suit or proceeding in connection with this Note may be brought against Maker in a federal or state court of record
located in Orange County, California, and Maker and Payee each agrees to submit to the personal jurisdiction of such court and
waives any objection which either may have, based on improper venue or forum non conveniens, to the conduct of any proceeding
in any such court and waives personal service of any and all process upon it, and consents that all such service of process be
made by mail or messenger directed to it at the address referred to in Paragraph 13(g) below and that service so made shall
be deemed to be completed upon the earlier of actual receipt or five (5) days after the same shall have been posted to its address.

 

(d)
Headings. The headings and captions of the various paragraphs herein are for convenience of reference only and shall in no way
modify any of the terms or provisions of this Note.

 

(e)
Loss, Theft, Destruction or Mutilation. Upon receipt by Maker of evidence reasonably satisfactory to it of loss, theft, destruction
or mutilation of this Note, Maker shall make and deliver or caused to be made and delivered to Payee a new Note of like date and
tenor in lieu of this Note.

 

(f)
Modification of Note or Waiver of Terms Thereof. No modification or waiver of any of the provisions of this Note shall be effective
unless in writing and signed by Maker and Payee and then only to the extent set forth in such writing, or shall any such modification
or waiver be applicable except in the specific instance for which it is given. This Note may not be discharged orally but only
in writing duly executed by Payee.

 

(g)
Notice. All offers, acceptances, notices, requests, demands and other communications under this Note shall be in writing and,
except as otherwise provided herein, shall be deemed to have been given only: (i) when delivered in person; (ii) one (1) day after
deposit with a nationally recognized overnight courier service; or, (iii) five (5) days after having been mailed by certified
or registered mail prepaid, to the parties at their respective addresses first set forth above, or at such other address as may
be given in writing in future by either party to the other. Notice may also be given via electronic or facsimile transmission
to a party who provides such party’s fax number or email address to the other party and shall be deemed to have been given
if receipt thereof is confirmed by the recipient.

 

(h)
Transfer. This Note shall be transferable only on the books of Maker upon delivery thereof duly endorsed by Payee or by Payee’s
duly authorized attorney or representative, or accompanied by proper evidence of succession, assignment, or authority to transfer.
In all cases of transfer by an attorney, executor, administrator, guardian, or other legal representative, duly authenticated
evidence of his, her or its authority shall be produced. Upon any registration of transfer, Maker shall deliver a new Note or
Notes to the person entitled thereto. Notwithstanding the foregoing, Maker shall have no obligation to cause Notes to be transferred
on its books to any person if, in the reasonable opinion of counsel to Maker, such transfer does not comply with the provisions
of the Act and the rules and regulations there under and/or applicable state securities laws.

 

(i)
Successors and Assigns. This Note shall be binding upon Maker, its successors, assigns and transferees, and shall inure to the
benefit of and be enforceable by Payee and Payee’s successors and assigns.

 

(j)
Severability. If one or more of the provisions or portions of this Note shall be deemed by any court or quasi-judicial authority
to be invalid, illegal or unenforceable in any respect, the invalidity, illegality or unenforceability of the remaining provisions,
or portions of provisions contained herein shall not in any way be affected or impaired thereby.

 

(k)
Gender. The use herein of the masculine pronouns or similar terms shall be deemed to include the feminine and neuter genders as
well and vice versa and the use of the singular pronouns shall be deemed to include the plural as well and vice versa.

 

(signature
page to follow)

 

    	Appendix A-15

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 16

    

 

 

NOTE
HOLDER NAME

 

IN
WITNESS WHEREOF, Maker has caused this Note to be executed on its behalf by an officer thereunto duly authorized as of the date
set forth above.

 

	 	Mateon Therapeutics, Inc. a Delaware corporation
	 	 	 
	 	By:	                      
	 	 	Vuong Trieu, President and CEO

 

ATTEST:___________________________

_________________,
Secretary

 

    	Appendix A-16

    	MateonTherapeutics, Inc.
16% Convertible Note
Page 17

    

 

 

NOTE
HOLDER NAME

 

ANNEX
A

 

NOTICE
OF CONVERSION

 

The
undersigned hereby elects to convert principal under the 16% Convertible Subordinated Unsecured Note due June 30, 2021 of Mateon
Therapeutics, Inc., a Delaware corporation (the “Company”), into shares of common stock (the “Common
Stock”), of __________________________according to the conditions hereof, as of the date written below. If shares
of Common Stock are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer taxes
payable with respect thereto and is delivering herewith such certificates and opinions as reasonably requested by the Company
in accordance therewith. No fee will be charged to the holder for any conversion, except for such transfer taxes, if any.

 

The
undersigned agrees to comply with the delivery requirements set forth in the Subscription Agreement and Investment Letter to which
this Notice of Conversion is appended as Annex A under the applicable securities laws in connection with any transfer of the aforesaid
shares of Common Stock.

 

Conversion
calculations:

Date
to Effect Conversion:

 

Principal
Amount of Debenture to be Converted: Number of shares of Common Stock to be issued:

 

Signature:

 

Name:

 

Address
for Delivery of Common Stock

 

Certificates:

 

Or

 

DWAC
Instructions:

 

Broker
No:________________

Account No:_______________

 

    	Appendix A-17Exhibit
10.6

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Registration Rights Agreement (this “Agreement”) is made and entered into as of July 23, 2020, by and among
Mateon Therapeutics, Inc. (the “Company”), a Delaware corporation with offices at 20397 Agoura Road, Suite
107, Agoura Hills, California 91301, and the investors signatories hereto (each a “Purchaser” and collectively,
the “Purchasers”). This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated
as of the date hereof, executed by each of the Purchasers and the Company (the “Subscription Agreement”).

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows:

 

1.
Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Subscription Agreement shall
have the meanings given such terms in the Subscription Agreement. As used in this Agreement, the following terms shall have the
respective meanings set forth in this Section 1.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 144.

 

“Business
Day” means any day except Saturday, Sunday and any day that shall be a federal legal holiday or a day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Commission”
means the Securities and Exchange Commission.

 

“Company’s
Common Stock” means the Company’s common stock, $0.01 par value per share.

 

“EdgePoint”
means EdgePoint AI, Inc., a EdgePoint corporation that is a wholly owned subsidiary of the Company.

 

“EdgePoint’s
Common Stock” means EdgePoint’s common stock, $0.001 par value per share.

 

“Effective
Date” means the date that the Registration Statement filed pursuant to Section 2(a) is first declared effective
by the Commission.

 

“Effectiveness
Date” means: (a) with respect to the initial Registration Statement required to be filed to cover the resale by the
Holders of the Registrable Securities, the earlier of:

 

(i)
the 120th day following the final Closing Date if the Commission does not review the Registration Statement or (ii) 150 days following
the final Closing Date if the Commission reviews the Registration Statement, and (b) with respect to any additional Registration
Statements that may be required pursuant to Sections 2(a) and (b) hereof, the earlier of: (i) the 120th day following
the date on which the Company first knows, or reasonably should have known, that such additional Registration Statement is required
under such Sections or

 

    	Appendix D-1

    	 

    

 

(ii)
the fifth trading day following the date on which the Company is notified by the Commission that such additional Registration
Statement will not be reviewed or is no longer subject to further review and comments. “Effectiveness Date”
shall also have the meaning specified in Section 2(b).

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Exchange
Act” means the Securities Exchange Act of 1934.

 

“Filing
Date” means: (a) with respect to the initial Registration Statement required to be filed to cover the resale by the
Holders of the Registrable Securities, the 90th day following the final Closing Date, and (b) with respect to any additional Registration
Statements that may be required pursuant to Sections 2(a) and (b) hereof, the 90th day following the date on which
the Company first knows, or reasonably should have known, that such additional Registration Statement is required under such Sections.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Notes”
means the convertible promissory notes included in a Unit that the Company is issuing to the Purchasers pursuant to the terms
of the Subscription Agreement that are convertible into the Company’s Common Stock and EdgePoint’s Common Stock

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering
of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by
reference in such Prospectus.

 

“Registrable
Securities” means the shares of EdgePoint Common Stock included in a Unit, the Warrants included in a Unit and the shares
of EdgePoint Common Stock and the Company’s Common Stock that may be issued upon conversion of the Notes and exercise of
the Warrants included in a Unit together with any securities issued or issuable upon any stock split, dividend or other distribution,
recapitalization or similar event, or any Note conversion rate or Warrant exercise price adjustment with respect thereto.

 

    	Appendix D-2

    	 

    

 

“Registration
Statement” means each of the following: (i) an initial registration statement which is required to register the resale
of the Registrable Securities, and (ii) each additional registration statement, if any, contemplated by Sections 2(a) and
(b), and including, in each case, the Prospectus, amendments and supplements to each such registration statement or Prospectus,
including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be
incorporated by reference in such registration statement.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Rule
415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933.

 

“Selling
Stockholders” shall have meaning defined in Section 3(b)(iii).

 

“Transfer
Agent” means the transfer agent for the Company’s Common Stock and EdgePoint’s’ Common Stock, as the
case may be.

 

“Transaction
Documents” means this Agreement, the Subscription Agreement, the Warrants, and any other documents or agreements executed
in connection with the transactions contemplated hereunder and in the Subscription Agreement.

 

“Unit”
means a unit consisting of the Notes, 250,000 shares of EdgePoint Common Stock, the Company Warrants and the EdgePoint Warrants.

 

“Warrants”
means an aggregate 50,000 Company Warrants each to acquire one share of Company Common Stock at an exercise price of $0.20 and
an aggregate 50,000 EdgePoint Warrants each to acquire one EdgePoint share of Common Stock at an exercise price of $1.00 subject
to applicable anti dilution provisions set forth in the Warrants.

 

2.
Registration.

 

(a)
Initial Registration Statements. On or prior to each Filing Date, the Company shall prepare and file with the Commission
a Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration
Statement for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement shall be on Form S-1,
or another appropriate form for such purpose, and shall contain (except if otherwise required pursuant to written comments received
from the Commission upon a review of such Registration Statement) the “Plan of Distribution” attached hereto as Annex
A. The Company shall cause the Registration Statement to be declared effective under the Securities Act as soon as possible
but, in any event, no later than the Effectiveness Date, and shall use its reasonable best efforts to keep the Registration Statement
continuously effective under the Securities Act until the date that is two years after the date that the Registration Statement
is declared effective by the Commission or such earlier date when all Registrable Securities covered by the Registration Statement
have been sold or may be sold pursuant to Rule 144(b)(i) as determined by the counsel to the Company pursuant to a written opinion
letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the “Effectiveness Period”).
It is agreed and understood that the Company shall, from time to time, be obligated to file an additional Registration Statement
to cover any Registrable Securities that are not registered for resale pursuant to a pre-existing Registration Statement.

 

    	Appendix D-3

    	 

    

 

(b)
Additional Registration Statements. If for any reason the Commission does not permit all of the Registrable Securities
to be included in the Registration Statement filed pursuant to Section 2(a), then the Company shall prepare and file as
soon as possible after the date on which the Commission shall indicate as being the first date or time that such filing may be
made, but in any event by the 90th day following such date, an additional Registration Statement covering the resale of all Registrable
Securities not already covered by an existing and effective Registration Statement for an offering to be made on a continuous
basis pursuant to Rule 415, on Form S-1 or another appropriate form for such purpose. Each such Registration Statement shall contain
(except if otherwise required pursuant to written comments received from the Commission upon a review of such Registration Statement)
the “Plan of Distribution” attached hereto as Annex A. The Company shall cause each such Registration Statement
to be declared effective under the Securities Act as soon as possible (the “Effectiveness Date”) and shall
use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act during the
entire Effectiveness Period.

 

(c)
Issuance of Legal Opinion.

 

(i)
Within three business days after the Effectiveness Date of a Registration Statement, the Company shall cause its counsel to issue
a blanket opinion in the form attached hereto as Exhibit A-1 or Exhibit A-2, as the case may be, (the “Form
Opinion”), to the Transfer Agent stating that the Shares, as defined therein, are subject to an effective registration
statement and can be reissued free of restrictive legend upon notice of a sale by the Purchaser and confirmation by the Purchaser
that it has complied with the prospectus delivery requirements, provided that the Company has not advised the Transfer Agent in
writing that the opinion has been withdrawn. Copies of the blanket opinion required by this Section 2(c) shall be delivered
to the Purchasers within the time period set forth above.

 

(ii)
In connection with Section 2(c)(i), the Company shall obtain confirmation from any new Transfer Agent, as may be engaged by the
Company from time to time, that the Form Opinion shall be sufficient to cause the removal of restrictive legends from the Shares
(as defined in the Form Opinion) and the Company shall provide confirmation of the same to the Purchasers.

 

3.
Registration Procedures. In connection with the Company’s registration obligations hereunder, the Company shall:

 

    	Appendix D-4

    	 

    

 

(a)
Not less than four trading days prior to the filing of a Registration Statement or any related Prospectus or any amendment or
supplement thereto, furnish to the Holders copies of all such documents proposed to be filed, which documents (other than those
incorporated by reference) will be subject to review by such Holders. The Company shall not file a Registration Statement or any
such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall,
in writing, reasonably object in good faith.

 

(b)
(i) Prepare and file with the Commission such amendments, including post- effective amendments, to each Registration Statement
and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective
as to the applicable Registrable Securities for its Effectiveness Period and prepare and file with the Commission such additional
Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause
the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended
to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible, and in any event within ten trading days,
to any comments received from the Commission with respect to each Registration Statement or any amendment thereto and, as promptly
as reasonably possible, provide the Holders true and complete copies of all correspondence from and to the Commission relating
to such Registration Statement that pertains to the Holders as selling stockholders (the “Selling Stockholders”)
but not any comments that would result in the disclosure to the Holders of material and non-public information concerning the
Company; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect
to the Registration Statements and the disposition of all Registrable Securities covered by each Registration Statement.

 

(c)
Notify the Holders as promptly as reasonably possible (and, in the case of (i)(A) below, not less than three trading days prior
to such filing) and (if requested by any such Holder) confirm such notice in writing no later than one trading day following the
day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed
to be filed; (B) when the Commission notifies the Company whether there will be a “review” of such Registration Statement
and whenever the Commission comments in writing on such Registration Statement (the Company shall provide true and complete copies
thereof and all written responses thereto to each of the Holders that pertain to such Holder as a Selling Stockholder or to the
Plan of Distribution, but not information which the Company believes would constitute material and non-public information); and
(C) with respect to each Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any
request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
Statement or Prospectus or for additional information that pertains to the Holders as Selling Stockholders or the Plan of Distribution;
(iii) of the issuance by the Commission of any stop order suspending the effectiveness of a Registration Statement covering any
or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company
of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable
Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and (v) of the occurrence
of any event or condition that makes the financial statements included in a Registration Statement ineligible for inclusion therein
or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein
by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other
documents so that, in the case of such Registration Statement or the Prospectus, as the case may be, it will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.

 

    	Appendix D-5

    	 

    

 

(d)
Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the
effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any
of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(e)
Furnish to each Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto
and all exhibits to the extent requested by such Holder (including those previously furnished or incorporated by reference) promptly
after the filing of such documents with the Commission; provided, however, that the Company shall have no obligation
to provide any document pursuant to this clause that is available on the EDGAR system.

 

(f)
Promptly deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (including each form of prospectus)
and each amendment or supplement thereto as such Holder may reasonably request. The Company hereby consents to the use of such
Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of
the Registrable Securities covered by such Prospectus and any amendment or supplement thereto.

 

(g)
Prior to any public offering of Registrable Securities, use its reasonable best efforts to register or qualify or cooperate with
the selling Holders in connection with the registration or qualification (or exemption from such registration or qualification)
of such Registrable Securities for offer and sale under the securities or Blue Sky laws of those jurisdictions within the United
States set forth on Schedule 3(g) hereto to keep each such registration or qualification (or exemption therefrom) effective
during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable the disposition in
such jurisdictions of the Registrable Securities covered by the Registration Statements; provided, however, that
neither the Company nor EdgePoint shall be required to qualify generally to do business in any jurisdiction where it is not then
so qualified or subject the Company or EdgePoint to any material tax in any such jurisdiction where it is not then so subject
or to take such actions in states that require merit review.

 

(h)
Cooperate with the Holders to facilitate the timely preparation and delivery of certificates representing Registrable Securities
to be delivered to a transferee pursuant to the Registration Statements, which certificates shall be free, to the extent permitted
by the Subscription Agreement and applicable law, of all restrictive legends, and to enable such Registrable Securities to be
in such denominations and registered in such names as any such Holders may request. The Company shall cause the Transfer Agent
to transmit the Registrable Securities to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission system if the Company is then a participant in such system.

 

    	Appendix D-6

    	 

    

 

(i)
Upon the occurrence of any event contemplated by Section 3(c)(v), as promptly as reasonably possible, prepare a supplement
or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus
or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that,
as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading.

 

The
Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock
beneficially owned by such Holder and any Affiliate thereof.

 

4.
Registration Expenses. All fees and expenses incident to the Company’s performance of its obligation under this Agreement
(excluding any underwriting discounts and selling commissions and all legal fees and expenses of legal counsel for any Holder)
shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees
and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including,
without limitation, fees and expenses (A) with respect to filings required to be made with the trading market on which the Common
Stock is then listed for trading, if any, and (B) in compliance with applicable state securities or Blue Sky laws), (ii) printing
expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses
if the printing of prospectuses is reasonably requested by the holders of a majority of the Registrable Securities included in
the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the
Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other
Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition,
the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions
contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing
legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing
of the Registrable Securities on any securities exchange as required hereunder.

 

    	Appendix D-7

    	 

    

 

5.
Indemnification.

 

(a) Indemnification
by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each
Holder, the officers, directors, agents, attorneys, investment advisors, partners, members, shareholders and employees of
each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act) and the officers, directors, agents, attorneys and employees of each such controlling Person, to the
fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs
(including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees) and expenses
(collectively, “Losses”), as incurred, arising out of or relating to any untrue or alleged untrue
statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any
amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or
in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required
to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or
supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only
to the extent, that (1) such untrue statements or omissions are based solely upon information regarding such Holder furnished
in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such
Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of
Prospectus or in any amendment or supplement thereto (it being understood that each Holder has approved Annex A hereto
for this purpose) or (2) in the case of an occurrence of an event of the type specified in Section 3(c)(ii)-(v), the
use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the
Prospectus is outdated or defective and prior to the receipt by such Holder of an Advice, as defined in Section 6(c) below,
or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or the
amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. The
Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of which the Company is
aware in connection with the transactions contemplated by this Agreement.

 

(b)
Indemnification by Holders. Each Holder shall, notwithstanding any termination of this Agreement, severally and not jointly,
indemnify and hold harmless the Company and EdgePoint, its directors, officers, agents, attorneys and employees, each Person who
controls the Company and EdgePoint, as the case may be (within the meaning of Section 15 of the Securities Act and Section 20
of the Exchange Act), and the directors, officers, agents, attorneys or employees of such controlling Persons, to the fullest
extent permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based solely upon: (x)
such Holder’s failure to comply with the prospectus delivery requirements of the Securities Act or (y) any untrue statement
of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or
supplement thereto, or arising solely out of or based solely upon any omission of a material fact required to be stated therein
or necessary to make the statements therein not misleading to the extent, but only to the extent that, (1) such untrue statements
or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly
for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution
of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in the Registration
Statement (it being understood that each Holder has approved Annex A hereto for this purpose), such Prospectus or such
form of Prospectus or in any amendment or supplement thereto or (2) in the case of an occurrence of an event of the type specified
in Section 3(c)(ii)-(v), the use by such Holder of an outdated or defective Prospectus after the Company has notified such
Holder in writing that the Prospectus is outdated or defective and prior to the receipt by such Holder of an Advice or an amended
or supplemented Prospectus, but only if and to the extent that following the receipt of the Advice or the amended or supplemented
Prospectus the misstatement or omission giving rise to such Loss would have been corrected. In no event shall the liability of
any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the
sale of the Registrable Securities giving rise to such indemnification obligation.

 

    	Appendix D-8

    	 

    

 

(c)
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity
is sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof,
including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof; provided, however, that the failure of any Indemnified Party to give such
notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only)
to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to
appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party.

 

An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying
Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed promptly to assume the
defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or
(3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying
Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same
counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies
the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying
Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Indemnifying Party);
provided, however, that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of
attorneys at any time for all Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any such Proceeding
effected without its written consent, which consent shall not be unreasonably withheld. No Indemnifying Party shall, without the
prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified
Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims
that are the subject matter of such Proceeding.

 

All
fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating
or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party,
as incurred, within ten trading days of written notice thereof to the Indemnifying Party (regardless of whether it is ultimately
determined that an Indemnified Party is not entitled to indemnification hereunder; provided, however, that the Indemnifying
Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it is finally judicially
determined that such Indemnified Party is not entitled to indemnification hereunder).

 

(d)
Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified
Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party,
shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is
appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements
or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying
Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or
made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount
paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in Section
5(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding
to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section
was available to such party in accordance with its terms.

 

    	Appendix D-9

    	 

    

 

The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined
by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required
to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from
the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise
been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.

 

The
indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties
may have to the Indemnified Parties.

 

6.
Miscellaneous

 

(a)
Remedies. In the event of a breach by the Company or by a Holder, of any of their obligations under this Agreement, each
Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this
Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company
and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach
by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it shall waive the defense that a remedy at law would be adequate.

 

(b)
Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities
Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement.

 

(c)
Discontinued Disposition. Each Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a
notice from the Company of the occurrence of any event of the kind described in Section 3(c), such Holder will forthwith
discontinue disposition of such Registrable Securities under the Registration Statement until such Holder’s receipt of the
copies of the supplemented Prospectus and/or amended Registration Statement or until it is advised in writing (the “Advice”)
by the Company that the use of the applicable Prospectus may be resumed, and, in either case, has received copies of any additional
or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement.
The Company may provide appropriate stop orders to enforce the provisions of this paragraph.

 

    	Appendix D-10

    	 

    

 

(d)
Amendments and Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by
the Company and the Holder or Holders (as applicable) of no less than a majority of the then outstanding Registrable Securities.
No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such
right.

 

(e)
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via electronic transmission at the or email address specified in this Section prior to 5:00 p.m. (California time)
on a Business Day, (ii) the Business Day after the date of transmission, if such notice or communication is delivered via electronic
transmission at the email address specified in this Agreement later than 5:00 p.m. (California time) on any date and earlier than
11:59 p.m. (California time) on such date, (iii) the Business Day following the date of dispatch, if sent by nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall be as follows:

 

If
to the Company:

 

Mateon
Therapeutics, Inc. 29397 Agoura Road

Suite
107

Agoura
Hills, CA 91301 Telephone:(650) 635-7002

Email
Address: ashah@oncotelic.com (with a copy to vtrieu@oncotelic.com)

	 	Attention:	Amit
    Shah, CFO
	 	 	 
	 	If
    to a Purchaser:	To
    the address set forth under such Purchaser’s name on the signature pages hereto.

 

If
to any other Person who is then the registered Holder:

 

To
the address of such Holder as it appears in the stock transfer books of the Company or such other address as may be designated
in writing hereafter, in the same manner, by such Person.

 

(f)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns
of each of the parties and shall inure to the benefit of each Holder. The Company may not assign its rights or obligations hereunder
without the prior written consent of each Holder. Holders may assign their respective rights hereunder in the manner and to the
Persons as permitted under the Subscription Agreement.

 

(g)
Execution and Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed
shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that
any signature is delivered by facsimile or electronic transmission, such signature shall create a valid binding obligation of
the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile
or electronic signature were the original thereof.

 

    	Appendix D-11

    	 

    

 

(h)
Governing Law; Venue. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard
to the principles of conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective Affiliates,
employees or agents) may be commenced in the state and federal courts sitting in Orange County, California. Each party hereto
hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a
copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in
effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way the right of a party to bring any action or proceeding
against another party or its property in the courts of any other jurisdiction or the right of a party to serve process in any
manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and
all right to trial by jury in any Proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
If any party shall commence a Proceeding to enforce any provisions of this Agreement, then the prevailing party in such Proceeding
shall be reimbursed by the other party for its attorney’s fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Proceeding.

 

(i)
Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

 

(j)
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the
parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such
that may be hereafter declared invalid, illegal, void or unenforceable.

 

(k)
Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof.

 

(l)
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser hereunder are several
and not joint with the obligations of any other Purchaser hereunder, and no Purchaser shall be responsible in any way for the
performance of the obligations of any other Purchaser hereunder. The decision of each Purchaser to purchase Units and/or Underlying
Securities pursuant to the Transaction Documents has been made independently of any other Purchaser. Nothing contained herein
or in any other agreement or document delivered at any closing, and no action taken by any Purchaser pursuant hereto or thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert with respect to such obligations or the transactions
contemplated by this Agreement. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection
with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring
its investment in the Units and/or Underlying Securities or enforcing its rights under the Transaction Documents. Each Purchaser
shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and
it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.

 

(m)
Gender. The use herein of the masculine pronouns or similar terms shall be deemed to include the feminine and neuter genders
as well and vice versa and the use of the singular pronouns shall be deemed to include the plural as well and vice versa.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGES TO FOLLOW]

 

    	Appendix D-12

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

	 	MATEON
    THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name:	Vuong
    Trieu
	 	Title:	Chief
    Executive Officer

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGES OF PURCHASER TO FOLLOW]

 

    	Appendix D-13

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.

 

_________________________

 

By:
_____________________________________________

 

Name:
___________________________________________

 

Title:____________________________________________

 

Address
for Notice:

_______________________

_______________________

_______________________

 

Email
Address:_____________________________

 

Attn.:_____________________________________

 

With
a copy to:

__________________________________________

__________________________________________

__________________________________________

 

Email
Address:______________________________

 

Attn:
______________________________________

 

    	Appendix D-14

    	 

    

 

ANNEX
A

J.H.
Darbie & Co., Inc. Plan of Distribution for Mateon Private Placement

 

J.H.
Darbie & Co., Inc. (“JHD”) is the distributor for this Private Placement in Mateon Therapeutics. This Regulation
D 506(c) offering is made to accredited investors and up to 35 non-accredited invetors. The offering is sold by private placement
memorandum, and all investors must meet the following criteia:

 

	 	●	received
    the private placement memorandum
	 	 	 
	 	●	complete
    a subcription agreement
	 	 	 
	 	●	registration
    rights offering

 

JHD
is under no obligation to purchase units of this offering and makes no guarantee the minimum number of units will be sold. The
private placement documents describe the investment minimums and timing of the first closing.

 

We
or our agents may solicit offers to purchase units on a best efforts basis for the period of its appointment.

 

In
connection with the sale of this offering JHD may receive compensation as described in the private placement agreeement and memorandum.

 

JHD
may invite other broker-dealers to participate in the distribution of this offering. Any other broker- dealer invited must be
approved by the issuer and will require appropriate amendments and diclosures to the accompanying offering documents and placement
agreement. Such dealers, may receive compensation in the form of discounts, concessions, or commissions from purchasers for whom
they may act as agents. We will identify any such dealer or agent, and we will describe any compensation paid to them in the related
private placement documents.

 

JHD
is obligated to sell A minimum of 40 units to close this private placement and may discontinue any sales activity at any time,
without prior notice. If 40 units cannot be sold, all funds will be returned to investors without financial penalty to them. Additionally,
the representatives of JHD may determine not to engage in selling transactions or that those transactions, once commenced, may
be discontinued without notice.

 

In
no event will the commission or discount received by JHD exceed fifteen percent of the aggregate principal amount of the offering
of these units of this private placement.

 

    	Appendix D-15

    	 

    

 

EXHIBIT
A-1

_______________________,
202_

 

American
Stock Transfer & Trust Company, LLC (AST)

 

Re:
Mateon Therapeutics, Inc.

 

Ladies
and Gentlemen:

 

As
counsel to Mateon Therapeutics, Inc., a Delaware corporation (the “Company”), we have been requested to consider
whether the legend referencing the registration requirements of the Securities Act of 1933(the “Act”), may
be removed from [•] shares (the “Shares”) of the Company’s common stock, par value $0.01 per share
(the “Common Stock”), held in book-entry form and consisting of [•] shares of Common Stock issued to [•]
and [•] Warrants (the “Warrants”) each exercisable to purchase [•] shares of the Company’s
common stock, held in book-entry form and consisting of [•] Warrants issued to [•].

 

The
Shares and Warrants were registered on a Registration Statement on Form [•] (File No. 333-[•]), initially filed by the
Company with the Securities and Exchange Commission (the “SEC”) on [•] (the “Registration Statement”)
and the related Prospectus dated [•] (as further supplemented from time to time, the “Resale Prospectus”)
relating to an aggregate of [•] shares (the “PIPE Shares”) of the Company’s Common Stock and Warrants
issued or to be issued to [•] and the other selling stockholders (together with [•], the “Selling Stockholders”)
identified in the Resale Prospectus. The Registration Statement registers the PIPE Shares and Warrants for resale by the Selling
Stockholders and was declared effective by the SEC on [•] at 4:30

p.m.
Eastern Time. We have no knowledge that any stop order suspending its effectiveness has been issued or that any proceedings for
that purpose are pending before, or threatened by, the SEC.

 

For
purposes of our opinion below, we have relied on the representations made by [•] in a representation letter dated as of [•]
and attached hereto as Exhibit A-1.

 

We
have assumed the genuineness of all signatures, the legal capacity of all individual signatories, the authenticity of all documents
submitted to us as originals, the conformity to original documents of documents submitted to us as certified or photostatic copies,
and the authenticity of such latter documents.

 

Based
upon the foregoing (including compliance with the representations referred to above), we are of the opinion that the restrictive
legend may be removed from the Shares.

 

Very
truly yours,

 

__________________________

__________________________

__________________________

 

    	Appendix D-16

    	 

    

 

EXHIBIT
A-2

______________________,
202_

 

American
Stock Transfer & Trust Company, LLC (AST)

 

Re:
EdgePoint AI, Inc.

 

Ladies
and Gentlemen:

 

As
counsel to EdgePoint AI, Inc., a Delaware corporation (the “Company”), we have been requested to consider whether
the legend referencing the registration requirements of the Securities Act of 1933(the “Act”), may be removed
from [•] shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common
Stock”), held in book- entry form and consisting of [•] shares of Common Stock issued to [•]and [•] Warrants
(the “Warrants”) each exercisable to purchase [•] shares of the Company’s common stock, held in
book-entry form and consisting of [•] Warrants issued to [•]..

 

The
Shares and Warrants were registered on a Registration Statement on Form [•] (File No. 333-[•]), initially filed by the
Company with the Securities and Exchange Commission (the “SEC”) on [•] (the “Registration Statement”)
and the related Prospectus dated [•] (as further supplemented from time to time, the “Resale Prospectus”)
relating to an aggregate of [•] shares (the “PIPE Shares”) of the Company’s Common Stock and Warrants
issued or to be issued to [•] and the other selling stockholders (together with [•], the “Selling Stockholders”)
identified in the Resale Prospectus. The Registration Statement registers the PIPE Shares and Warrants for resale by the Selling
Stockholders and was declared effective by the SEC on [•] at 4:30

p.m.
Eastern Time. We have no knowledge that any stop order suspending its effectiveness has been issued or that any proceedings for
that purpose are pending before, or threatened by, the SEC.

 

For
purposes of our opinion below, we have relied on the representations made by [•] in a representation letter dated as of [•]
and attached hereto as Exhibit A-2.

 

We
have assumed the genuineness of all signatures, the legal capacity of all individual signatories, the authenticity of all documents
submitted to us as originals, the conformity to original documents of documents submitted to us as certified or photostatic copies,
and the authenticity of such latter documents.

 

Based
upon the foregoing (including compliance with the representations referred to above), we are of the opinion that the restrictive
legend may be removed from the Shares.

 

Very
truly yours,

 

________________________

________________________

________________________

 

    	Appendix D-17

    	 

    

 

SCHEDULE
3(g)

 

BLUE
SKY JURISDICTIONS

AND/OR

STATES
OF SOLICITAION

 

ALL
STATES

 

    	Appendix D-18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]